Grand Pharmaceutical to Acquire Two Biotech and Fine Chemical Units in RMB316 Million Connected Deal

Grand Pharmaceutical Group Limited ( (HK:0512) ) has provided an announcement.

Grand Pharmaceutical Group Limited has announced that its subsidiary Hubei Yuanda will acquire 100% of the equity interests in Hebei Yuanda Jiufu Biotechnology Co., Ltd. and Baoding Jiahe Fine Chemical Co., Ltd. for a total consideration of RMB316 million, turning both target entities into indirectly wholly owned subsidiaries. The deal, which involves the purchase of stakes from China Grand (the company’s 53.42% shareholder) and another vendor, is classified as a connected transaction under Hong Kong listing rules but only requires reporting and announcement rather than independent shareholders’ approval, and was priced after arm’s length negotiations based on an independent valuation and the targets’ financial performance, assets and R&D prospects, reflecting Grand Pharmaceutical’s intention to capture expected benefits from these businesses and further integrate biotech and fine chemical capabilities into its group structure.

The most recent analyst rating on (HK:0512) stock is a Buy with a HK$10.00 price target. To see the full list of analyst forecasts on Grand Pharmaceutical Group Limited stock, see the HK:0512 Stock Forecast page.

More about Grand Pharmaceutical Group Limited

Grand Pharmaceutical Group Limited is a Hong Kong-listed pharmaceutical company engaged in the research, development, production and sale of pharmaceutical products and related technologies, with operations in mainland China through subsidiaries such as Hubei Yuanda. The group focuses on expanding its portfolio and capabilities in biotech and fine chemical segments to strengthen its position in the broader healthcare and life sciences market.

Average Trading Volume: 5,963,809

Technical Sentiment Signal: Buy

Current Market Cap: HK$27.94B

For a thorough assessment of 0512 stock, go to TipRanks’ Stock Analysis page.